Drugs / bacTRL-Spike
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04334980 | Nov 2020 → Aug 2022 | COVID-19 | Symvivo Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bacTRL-Spike | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04334980 ↗ |
| Modality | Vaccine | “bacTRL-Spike Oral Candidate Vaccine” NCT04334980 ↗ |
| Route | Oral | “Each oral dose of bacTRL-Spike contains bacterial medium” NCT04334980 ↗ |